Intra-articular Injection in Arthroscopic Management of Temporomandibular Diseases

June 18, 2021 updated by: Ahmad Mohammad Abd-elmoniem, Sohag University

Comparative Study Between the Outcome of Intra-articular Injection of Platelet Rich Plasma Versus Hyaluronic Acid in Arthroscopic Management of Temporomandibular Degenerative Joint Diseases: A Randomized Clinical Trial

The aim of this study is to evaluate the efficacy of intra-articular injection of platelet rich plasma versus hyaluronic acid following diagnostic arthroscopy in the management of patients suffering from degenerative temporomandibular joint (TMJ).

This is a prospective randomized study of 20 patients with TMJ degenerative joint diseases Wilkes IV, V.

Patients will be divided into two groups; Group A: will be treated with operative arthroscopy plus intra-articular platelet rich plasma.

Group B: will be treated with operative arthroscopy plus intra-articular hyaluronic acid.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • - All patients with reduced mouth opening and/or painful maximum mouth opening.
  • Joint pain.
  • Patients with radiological evidence of degenerative joint disease.
  • Patients with unsuccessful medical conservative treatment for at least two months.
  • Unilateral or bilateral temporomandibular joint involvement.
  • Wilkes stages IV and V

Exclusion Criteria:

  • - Patients with bony ankylosis .
  • Patients with advanced resorption of the glenoid fossa.
  • Patients with infection or tumors around joint area
  • Patients unfit for intervention medically.
  • Patients who refused to share in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: arthroscopy plus platelet rich plasma.
Group A: will be treated with operative arthroscopy plus intra-articular injection of platelet rich plasma
patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.
Active Comparator: arthroscopy plus hyaluronic acid.
Group B: will be treated with operative arthroscopy plus intra-articular injection of hyaluronic acid
patients with TMJ degenerative joint diseases Wilkes stages IV, V not responding to conservative treatment will undergo operative diagnostic arthroscopic treatment then at the end of the procedure intra-articular injection of platelet rich plasma or hyaluronic acid will be done.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in maximum inter-incisal mouth opening
Time Frame: change from baseline maximum interincisal mouth opening in millimeters at 6 months postoperative
change in maximum inter-incisal mouth opening will be measured in millimeters
change from baseline maximum interincisal mouth opening in millimeters at 6 months postoperative
Change in pain intensity
Time Frame: change from preoperative pain intensity according to 100 -point visual analogue scale at 6 months postoperative
A 100 -point visual analogue scale (VAS) for the assessment of pain intensity with 0 as the absence of pain and 100 as the worst pain imaginable With filled standardized charts.
change from preoperative pain intensity according to 100 -point visual analogue scale at 6 months postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Samia M Saied, MD, PROFESSOR

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 13, 2021

Primary Completion (Anticipated)

June 13, 2022

Study Completion (Anticipated)

June 1, 2023

Study Registration Dates

First Submitted

June 13, 2021

First Submitted That Met QC Criteria

June 18, 2021

First Posted (Actual)

June 23, 2021

Study Record Updates

Last Update Posted (Actual)

June 23, 2021

Last Update Submitted That Met QC Criteria

June 18, 2021

Last Verified

June 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Temporomandibular Joint Disorders

Clinical Trials on Temporomandibular joint arthroscopy plus intra-articular injection

Subscribe